AZD7760
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Staphylococcus Aureus
Conditions
Staphylococcus Aureus
Trial Timeline
Dec 30, 2024 → Jul 6, 2027
NCT ID
NCT06749457About AZD7760
AZD7760 is a phase 1/2 stage product being developed by AstraZeneca for Staphylococcus Aureus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06749457. Target conditions include Staphylococcus Aureus.
What happened to similar drugs?
2 of 4 similar drugs in Staphylococcus Aureus were approved
Approved (2) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06749457 | Phase 1/2 | Recruiting |
Competing Products
12 competing products in Staphylococcus Aureus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin | AbbVie | Phase 3 | 40 |
| V710 + Placebo | Merck | Phase 2/3 | 30 |
| Daptomycin | Merck | Phase 2 | 35 |
| Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) | Merck | Phase 2 | 35 |
| Imipenem/cilastatin | Pfizer | Approved | 39 |
| linezolid (Zyvox) + vancomycin | Pfizer | Approved | 43 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 26 |
| Aurexis® | Bristol Myers Squibb | Phase 2 | 35 |
| Aurexis® (tefibazumab) | Bristol Myers Squibb | Phase 2 | 35 |
| blood samples + nasal swabs | Sanofi | Pre-clinical | 26 |
| Ceftobiprole medocaril + Daptomycin | Basilea Pharmaceutica | Phase 3 | 34 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | XBiotech | Phase 1/2 | 22 |